Fusion Pharmaceuticals CEO John Valliant's 2021 pay falls 53% to $3.3M
Fusion Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Fusion Pharmaceuticals reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, three executives at Fusion Pharmaceuticals received on average a compensation package of $2.6M, a 18% decrease compared to previous year.
Average pay of disclosed executives at Fusion Pharmaceuticals
John Valliant, Chief Executive Officer, received $3.3M in total, which decreased by 53% compared to 2020. 73% of Valliant's compensation, or $2.4M, was in option awards. Valliant also received $260K in non-equity incentive plan, $597K in salary, as well as $31K in other compensation.
Eric Burak, Chief Scientific Officer, received a compensation package of $3M, which increased by 62% compared to previous year. 78% of the compensation package, or $2.3M, was in option awards.
John Crowley, Chief Financial Officer, earned $1.6M in 2021, a 2% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 29, 2022.